Health Canada approves KEYTRUDA and Enfortumab Vedotin for advanced urothelial cancer
Merck (NYSE: MRK), known as MSD outside the United States and Canada, has announced that Health Canada has granted approval for KEYTRUDA (pembrolizumab) in combination ... Read More
Pfizer’s CIFFREO Phase 3 study in DMD fails to meet primary endpoint
Pfizer Inc. (NYSE: PFE), a global leader in pharmaceuticals, faced a setback as their CIFFREO Phase 3 study did not meet its primary endpoint. The ... Read More
Pfizer secures FDA approval for Hemophilia B gene therapy BEQVEZ
Pfizer Inc. (NYSE: PFE) announced a significant breakthrough in hemophilia treatment with the U.S. Food and Drug Administration's approval of BEQVEZ (fidanacogene elaparvovec-dzkt), a pioneering ... Read More
EC authorizes Pfizer’s PREVENAR 20 vaccine for pediatric Use
In a landmark decision, Pfizer Inc. (NYSE: PFE) has been granted marketing authorization by the European Commission (EC) for its 20-valent pneumococcal conjugate vaccine, PREVENAR ... Read More
Genmab, Pfizer’s tisotumab vedotin takes a leap towards EU approval for cervical cancer
In a significant development for cervical cancer treatment, Genmab A/S (Nasdaq: GMAB) and Pfizer, Inc. (NYSE: PFE) have announced the European Medicines Agency's (EMA) validation ... Read More
Advancing bladder cancer treatment: EMA scrutinizes Astellas-Pfizer’s innovative therapy
A groundbreaking development in bladder cancer treatment is on the horizon as Astellas Pharma Inc. and Pfizer Inc. await the European Medicines Agency’s (EMA) review ... Read More
Pfizer’s immunotherapy ELREXFIO approved in EU for multiple myeloma
Pfizer Inc. has announced a significant development in the treatment of multiple myeloma, a type of cancer that affects plasma cells in the bone marrow. ... Read More
Pfizer’s danuglipron shows promising results in Phase 2b obesity trial
Pfizer Inc. (NYSE: PFE) has announced encouraging topline data from its Phase 2b clinical trial (NCT04707313) investigating danuglipron, an oral Glucagon-like peptide-1 receptor agonist (GLP-1RA), ... Read More
Aurobindo Pharma subsidiary earns FDA approval for Testosterone Cypionate Injection
In a significant development for the pharmaceutical industry, Aurobindo Pharma Limited's dedicated subsidiary, Eugia Pharma Specialities Limited, has triumphantly gained the final nod from the ... Read More
Lupin gains FDA nod for generic Diflucan Tablets production
Lupin Limited, a recognized global pharmaceutical powerhouse, proudly announced its receipt of the much-anticipated approval from the US Food and Drug Administration (FDA). This authorization ... Read More